bra. These selection characteristics potentially magnify the hypothesized harm of hyperglycemia in this subset of patients with AIS. To our knowledge, the literature offers no large study examining the impact of hyperglycemia in the setting of endovascular intervention for AIS.
In the CARDINAL trial, the relative change in blood glucose at 48 hours from the baseline admission value predicted death after intervention for MI. 12 Although the post hoc analysis of the European and Australian Cooperative Stroke Study II showed that hyperglycemia at 24 hours was associated with higher risk of death and worse outcome at 7 days, 31 there are no large studies testing a similar effect on patients who undergo AIS and endovascular intervention.
In this multicenter retrospective study, we tested the hypothesis that BGA and CG48 in nondiabetic and diabetic patients after endovascular AIS therapy would significantly correlate with 90-day poor functional outcomes. In addition, we developed a simplified stroke prognostic scale that incorporates blood glucose values to model 90-day outcomes after AIS intervention. Substantial explanatory power in our retrospective study would support its prospective assessment as a prognostic tool.
Methods
We performed a retrospective pooled analysis of data that had been prospectively collected from 614 patients at 7 different US centers who underwent endovascular therapy for AIS between January 2005 and June 2009 and who had 2 blood glucose values (one at admission and another between 24 and 48 hours later). The institutional review boards at the individual centers and the coordinating center (University at Buffalo) waived the requirement to obtain consent from the individual patients for the retrospective review and analysis of the data. An Excel spreadsheet (Microsoft Corp.) with common data points was sent to all participating centers, and deidentified data were pooled at the coordinating center and analyzed. Only the data for patients who had completed 3 months of follow-up (including the mRS score) were sent to the coordinating center and included in the analysis.
Data Collected
Blood Glucose Values. These were measured at admission and between 24 and 48 hours (the level closest to 48 hours was used for analysis when more than 1 value was available).
Patient Demographic Data and Presentation. Age, sex, history of comorbid conditions (such as diabetes, hyperlipidemia, hypertension, atrial fibrillation, and smoking), presentation NIHSS score, and previous intravenous thrombolysis.
Time to Treatment Initiation. This variable reflected time from symptom onset to femoral artery puncture for endovascular therapy. This categorical variable was classified into the following fields: 1) AC strokes treated within 8 hours of onset (AC < 8 hours); 2) AC strokes treated 8 or more hours after onset (AC ≥ 8 hours); 3) AC WUSs; and 4) PC strokes.
Occlusion Locations. Extracranial carotid, carotid terminus, tandem extracranial-intracranial, M 1 and M 2 segments of the middle cerebral artery, and PC.
Type of Endovascular Therapy. Intraarterial thrombolysis, Merci device (Concentric Medical, Inc.), Penumbra device (Penumbra, Inc.), intracranial stent placement, extracranial stent placement, intracranial thrombus disruption (including wire manipulation and balloon angioplasty), and eptifibatide.
Results of Therapy. Therapy results divided into 2 distinct binary variables: 1) TIMI Grade 2-3 reperfusion, 27 and 2) posttreatment ICHs (asymptomatic and symptomatic if the NIHSS score decreased by 4 or more points). Patients routinely underwent a postprocedural CT scan.
Outcomes at 90 Days. These were quantified using the mRS score (0-2, good outcome; 3-6, poor outcome [includes death]; and 6, death). The mRS scores of 3-6 and 6 were the dependent variables in the regression model.
The presentation NIHSS score, type of posttreatment hemorrhage, posttreatment recanalization (TIMI), and outcomes (categorized based on mRS score) were graded at the individual centers. The time to treatment initiation and CG48 were calculated at the coordinating center. The CG48 values were categorized by the coordinating center as a > 30 mg/dl (> 1.7 mmol/L) drop from the admission value, a 0-30 mg/dl (0-1.7 mmol/L) drop from the admission value, and a rise from the admission value, in accordance with the scheme used for the CARDINAL study.
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The diabetic status was obtained from the patient's medical history, and patients were not proactively screened for undiagnosed diabetes.
Statistical Analysis
The PASW/SPSS version 18.0 software (SPSS, Inc.) was used for statistical analysis. The end points analyzed were 90-day mortality rates (mRS Score 6) and 90-day poor outcome (mRS Score 3-6). The continuous variables of age, presentation NIHSS score, and BGA were explored against mRS at 90 days with an auto-binning program and histograms to search for optimal cutoffs based on which of these variables could be categorized. The categories of CG48 (as in the CARDINAL data 12 ) in the identified individual BGA categories (as derived from our multicenter data) were explored to depict differences in 90-day outcomes (good outcomes were defined as mRS Score 0-2, and death as mRS Score 6) by histograms. The differences in demographics, presentation characteristics, occlusion locations, therapy types, therapy results, and 90-day outcomes were compared within the identified BGA categories by using the Pearson chisquare test/ordinal gamma test for categorical variables and 1-way ANOVA for continuous variables. Pearson correlation analysis was performed to look for correlations between BGA as a continuous variable and other variables (all continuous variables were used as continuous and not categorized).
Univariate analysis of the potential covariates (shown in Table 1 ) was performed to look for predictors of end points with p < 0.2. This was done to reduce the number of potential predictors included in the logistic regression model, and thus would avoid overmodeling. Multivariate stepwise forward logistic regression models were built in 2 different hierarchical steps, with admission and posttreatment covariates (those having p values < 0.2) identified by univariate analysis to determine independent predictors of end points. Individual logistic regression models were built for the total group, for nondiabetic patients, diabetic patients, and for predictors of death and poor outcome. Adjusted ORs with 95% CIs were derived for significant predictors from the multivariate model (p < 0.05 was considered significant). In the categorical variables, age < 68 years, NIHSS score < 16, BGA < 116 mg/ dl (< 6.4 mmol/L), and a > 30 mg/dl (> 1.7 mmol/L) drop in CG48 were used as reference categories for calculating the adjusted OR.
Prognostic Scale Derivation and Evaluation
A simplified point scoring system was developed from the data to predict 90-day poor outcomes. We used the beta coefficients of highly significant predictors from the multivariate logistic regression models in the total group to weight the predictors. The predictors in this scoring scale were classified as predictors at admission and predictors postintervention at 48 hours. A final score (with all predictors) and an admission score (with predictors at admission) were calculated for each patient by adding the individual scores of the predictors.
Measures of Discrimination and Validation of the Developed Score
The ROC analyses were performed after each multivariate logistic regression model, and the ROC AUCs were compared for accuracy of the final logistic regression model, with significant predictors in foreseeing poor outcomes. An AUC of 1.0 indicates perfect discrimination, whereas an AUC of 0.5 indicates discrimination that is no better than random chance. Generally, an AUC of ≥ 0.70 is considered a clinically useful predictive model. 26 For example, a well-respected model for predicting adverse outcomes after coronary artery bypass grafting had an AUC of 0.73. 9 The ROC analysis of the final and admission scores was performed, and AUCs were compared with the final logistic regression models with the significant independent predictors for accuracy of predicting poor outcomes in the total group, in nondiabetic patients, and in diabetic patients. Determining the discrepancies between the predicted and actual poor outcomes and obtaining the Hosmer-Lemeshow goodness-of-fit statistics calibrated the final and admission scores. A HosmerLemeshow statistic of < 0.05 rejects the null hypothesis that there is no difference, implying that the model's estimates fit the data at an acceptable level. Internal validation of the scores was performed by repeatedly calculating the AUC by using 1000 bootstrap resamples of the data set and calculating the difference between the AUC of the test sample and that of the average of the AUC of all bootstrap samples. External validation of the BRANCH score was performed on retrospective data collected in 55 patients who underwent endovascular stroke therapy at 2 other institutions different from the 7 institutions where the score was developed.
Risk-Benefit Analysis Based on Admission Score
An algorithm for risk-benefit analysis before endovascular therapy was derived based on outcomes of patients in admission and final score categories.
Results

Demographic Data
This study included 614 patients with AIS whose average age was 67.3 ± 16.2 years (mean ± SD; median 70 years; interquartile range 57-80 years). Of the patients studied, 52.6% were women, 67.9% were known to have hypertension, 43.1% were known to have dyslipidemia, 27.3% were known to have diabetes (diabetic status was not known in 5 patients), 35% had a history of atrial fibrillation, and 29.8% were smokers (Table 1) .
Presentation and Therapy
The mean (± SD) presentation NIHSS score was 16.1 ± 6.1 (median 16, interquartile range [12] [13] [14] [15] [16] [17] [18] [19] [20] 
Blood Glucose Values
Blood glucose values and distributions are summarized in Table 2 . different categories that affected the final prognosis in these patients, and the cutoff points came from the data and were not prespecified. Increasing BGA categories (p < 0.001), age categories (p < 0.001), and presentation NIHSS categories (p < 0.001) showed a statistically significant increase in poor outcomes (mRS Score 3-6) and death (mRS Score 6).
Categorization of Continuous Variables
Comparison Among BGA Categories
As expected, the CG48 drop was greater in patients with higher BGA (p < 0.001). The proportions of diabetic patients (p < 0.001), hypertensive patients (p = 0.019), and patients with higher NIHSS score at presentation (p = 0.009) were greater in patients with a higher BGA; and there was a higher percentage of PC strokes (p = 0.001) and a lower percentage of use of eptifibatide (p = 0.017) in patients with BGA > 142 mg/dl (> 7.9 mmol/L). The BGA had a statistically significant correlation with known diabetes (p < 0.001), a CG48 rise (p < 0.001), death (p < 0.001), poor outcomes (p < 0.001), use of eptifibatide (p = 0.004), PC strokes (p = 0.003), presentation NIHSS score (p = 0.002), and history of hypertension (p = 0.011). Table 3 shows the identified predictors on univariate analysis of poor outcome and death in the total group, in nondiabetic patients, and in diabetic patients with a p value < 0.2. Patients with increasing age (p < 0.001) and higher NIHSS (p < 0.001) and BGA categories (p < 0.001) had a significantly greater chance of poor outcomes and death in all 3 groups. Patients with a CG48 increase had a greater chance of a poor outcome in the total group (p = 0.004) and the nondiabetic group (p < 0.001), whereas CG48 did not reach statistical significance in diabetic patients (p = 0.707). Patients with diabetes had a greater chance of poor outcome overall (p = 0.038).
Univariate Analysis
Outcomes by CG48 Categories in Each BGA Category
Figures 2-4 show histograms of 90-day mRS categories (mRS Scores 0-2, 3-5, and 6 [the latter is designated "mortality" in the figure]) plotted against CG48 categories in each BGA category for the total group, nondiabetic patients, and diabetic patients. Increasing CG48 was associated with a statistically significant trend toward an increase in poor outcomes (mRS Score 3-6) and increasing mortality rates in the total group (Fig. 2 ) and in nondiabetic patients (Fig. 3) . Although similar trends were seen in diabetic patients with increasing BGA categories, the increasing CG48 categories did not show any statistically significant trend to 90-day outcomes (Fig. 4) .
Multivariate Analysis
For mortality models, the least frequency outcomes in the total, nondiabetic, and diabetic categories were 189 (5 patients with unknown diabetes status died), 128, and 56 patients, respectively; and the number of predictors used in the logistic regression analysis was 10, 10, and 4, respectively. For the mRS Score 3-6 models, the least frequency outcomes in the total, nondiabetic, and diabetic categories were 375, 258, and 112 patients, respectively; and the number of predictors used in the logistic regression analysis was 14, 13, and 5, respectively. Table 4 shows the significant predictors, along with adjusted ORs and 95% CIs, in the individual binary logistics regression models.
In nondiabetic patients, increasing BGA categories (116-142 mg/dl vs < 116 mg/dl: OR 2.04, p = 0.019; > 142 mg/dl vs < 116 mg/dl: OR 7.43, p < 0.001) and increasing CG48 categories (a 0-30 mg/dl drop vs a > 30 mg/ dl drop: OR 3.09, p = 0.001; a rise vs a > 30 mg/dl drop: OR 4.49, p < 0.001) were independent predictors of death. Increasing BGA categories (116-142 mg/dl vs < 116 mg/ dl: OR 2.14, p = 0.007; > 142 mg/dl vs < 116 mg/dl: OR 5.83, p < 0.001) and increasing CG48 categories (a 0-30 mg/dl drop vs a > 30 mg/dl drop: OR 2.04, p = 0.012; a rise vs a > 30 mg/dl drop: OR 6.42, p < 0.001) were also independent predictors of poor outcome at 90 days.
In patients with diabetes, higher BGA categories (116-142 mg/dl vs < 116 mg/dl: OR 6.88, p = 0.002; > 142 mg/dl vs < 116 mg/dl: OR 5.25, p = 0.001) were an independent predictor of death, whereas BGA categories were not independent predictors of poor outcome at 90 days. The CG48 categories were not an independent predictor of death or poor outcome in diabetic patients. In the total group, increasing BGA categories (116-142 mg/dl vs < 116 mg/dl: OR 
Prognostic Scale Derivation and Evaluation
As shown by the results of the binary logistic regression analysis for poor outcome and death in the total group (Table 4) , the significant admission predictors of poor outcome were BGA categories, NIHSS categories, and age categories. The significant postintervention predictors of worse outcome were TIMI Grade 2-3 reperfusion, sICH, and CG48 categories. These predictors were given a score, as shown in Table 5 , and weighted by their relative beta coefficients in the logistic regression models in all patients. The CG48 categories were scored as 0, 1, and 2. If future studies show that glucose-lowering therapy can improve outcomes, more appropriate scores of the CG48 categories will be -1, 0, and 1. The sum of all the predictor scores in the scoring system (final score), as well as the sum of admission predictor scores in the scoring system (admission score), was calculated for each patient. The elements of the final score are represented by the acronym BRANCH, and those of the admission score are represented by the acronym BAN.
Measures of Discrimination, Internal Validation, and External Validation
The individual logistic regression models were able to predict 90-day poor outcome with AUC > 0.8, compared with > 0.79 using the final score and > 0.73 using the admission score ( Table 6 ). The BRANCH and BAN scores therefore adequately captured the logistic regression model's explanatory power in describing the variance in 90-day outcome. The prognostic utility, however, requires prospective validation. The proposed scores reflect the observed variance in glycemic control. Figure 5 shows the results of calibration and internal validation by Hosmer-Lemeshow statistics of the final and admission scores, respectively. The expected rate of poor outcomes as calibrated from the scores and the observed rates of poor outcome in our patient population are plotted against each category of the score in the x axis. Note that patients with an admission score or a final score of ≥ 4 have a dismal 90-day prognosis, and that the scores correspond with expected outcomes very closely. The Hosmer-Lemeshow statistic in the total group for the final score was 2.50 (p = 0.77) and the admission score was 0.43 (p = 0.98), implying that estimates of both final and admission models fit the data at a threshold level.
When the BRANCH score was calculated in 55 patients from 2 centers (which were different from the 7 centers at which the score was developed) and explored against the percentage of patients who had poor 90-day 
Risk-Benefit Algorithm
The Spearman rho correlation coefficient for admission and final scores was 0.791, p < 0.001. Figure 6 upper shows the percentage of patients with different final scores in each admission score category. From our calibration, we know that patients with a final score of ≥ 4 have a dismal 90-day outcome (shaded in red). Furthermore, only 3%-11% of patients with an admission score of 0-2 progressed to a final score of ≥ 4 and a poor outcome. In patients with an admission score of 3-4, the chance of having a final score of ≥ 4 and a poor outcome was 35%-55%.
Among patients with an admission score of 3-4, not surprisingly, clinical outcome is largely reliant on technical procedural success. It is very important to achieve TIMI Grade 2-3 reperfusion (this subtracts 1 from the admission score) and avoid sICH (avoids getting 2 points on the final score) to avoid a poor outcome. Patients with an admission score of 5-6 ultimately receive a final score of ≥ 4 and experience a poor 90-day outcome, independent of revascularization. Triage in this manner prospectively may confirm the futility of endovascular therapy in these patients.
In sum, Fig. 6 lower shows proposed zones for prognostication in patients chosen for endovascular therapy from the logic derived in Fig. 6 upper. Retrospective analysis suggests that patients with an admission score of 0-2 uniformly enjoy a good outcome after endovascular therapy. Intermediate scores of 3-4 require strict risk-benefit analysis for endovascular therapy selection. Avoidance of sICH in a patient with an admission score of 3-4 is critical to prevent an iatrogenic final score of > 4. Patients with an admission score of 5-6 exhibit questionable benefit with endovascular therapy and inevitably receive a final score of > 4.
Discussion
In this study, BGA ≥ 116 mg/dl and failure of CG48 to drop > 30 mg/dl were significant (p < 0.001) independent predictors of 90-day outcomes in nondiabetic patients, both in terms of mortality rate and functional independence after AIS intervention. In diabetic patients, BGA ≥ 116 mg/dl was an independent predictor of death, whereas CG48 did not affect outcomes at 90 days. The BGA value was as predictive as age, NIHSS score, and sICH, which have been traditionally used as covariates in stroke outcome analysis, and as has been previously reported with intravenous thrombolysis. 4 Although there was a correlation between the NIHSS score and BGA, both BGA and NIHSS score were independent predictors of 3-month outcome in the multivariate model. The ability of the simplified 3-point admission score to capture the variance in 90-day outcomes after stroke reliably-even in nondiabetic patients-reemphasizes the importance of blood glucose measurement in all patients with AIS as a potentially prognostic marker. Indeed, our analysis suggests that BGA and CG48 carry greater clinical import in nondiabetic patients. Although previous studies have shown increasing glucose to be predictive of poor outcome after AIS, blood glucose values as low as 116 mg/ dl have previously not been shown to be associated with worse outcomes.
In our study, a CG48 rise was also a significant predictor of poor outcome and death in nondiabetic patients. In contrast, CG48 did not predict outcomes in diabetic patients. The CG48 increase in nondiabetic patients in each BGA category (Fig. 3) shows a very significant relationship between the proportion of patients with poor outcomes and death. Interestingly, this is consistent with the results of the CARDINAL study in patients with MI.
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It remains unclear whether this hyperglycemia arises as an epiphenomenon of stroke severity or as a reflection of an underlying disturbance in metabolism. 17 Although the CG48 was not normalized to the NIHSS and could be a reflection of the stroke severity, both NIHSS score and CG48 were independent predictors of 3-month outcomes.
From a therapeutic standpoint, the durability of CG48 statistical significance suggests the potential to mitigate against the harm of acute hyperglycemia with tighter control in the clinical setting. Caution should be taken in evaluating this hypothesis, because tight glucose control may be deleterious due to the possibility of insulin-induced hypoglycemia. 19 In our experience, this would make continuous glucose monitoring essential in these patients to avoid hypoglycemia despite attempting to maintain tight glucose control.
The difference in mortality rate and poor outcomes in each CG48 category generates the hypothesis that a glucose-lowering strategy may be effective in improving clinical outcomes in patients with AIS who are treated with endovascular therapy. The use of intravenous insulin infusion to achieve this end has been shown to be beneficial in acute MI because of the ability of insulin to exert powerful antiinflammatory and antiapoptotic effects. 6, 16 Albeit at present, no data exist to support this hypothesis in AIS, and this needs to be tested by a prospective randomized trial.
The largest randomized controlled trial of glucoselowering therapy in AIS, the United Kingdom Glucose Insulin in Stroke Trial, did not show any benefit of glucose lowering with glucose-insulin-potassium infusions for 24 hours after stroke onset. 13 The main limitations of the trial were that it was stopped early due to slow patient enrollment and that it was underpowered. The glucose reduction achieved in the treatment arm was only 9 mg/ dl (0.5 mmol/L) when compared with the control arm, and the attempt to reduce glucose was stopped as early as 24 hours. The presence of a substantial proportion of diabetic patients may dilute a possible therapeutic effect and requires dedicated evaluation. Additionally, our data suggest a benefit only in nondiabetic patients.
Preclinical evidence from animal models of global and focal cerebral ischemia indicates that insulin is capable of attenuating brain injury and improving neurological outcome, even independent of its glucose-lowering effect. 10, 14, 28, 29, 32 Two small pilot insulin infusion trials, the Treatment of Hyperglycemia in Ischemic Stroke trial 3 and the Glucose Regulation in Acute Stroke Patients trial, 15 have been shown to achieve higher glucose reduction compared with glucose-insulin-potassium regimens, although they had a higher rate (30%-33%) of asymptomatic hypoglycemia. Because ischemic stroke is a proinflammatory condition, it is important to examine the proinflammatory effects of glucose and the antiinflammatory and other relevant effects of insulin, independent of its glucose-lowering effect. 7 After intravenous thrombolysis, the recanalization benefit obtained from recombinant tissue plasminogen activator appears to be partially negated by glucose concentrations ≥ 140 mg/dl (≥ 7.8 mmol/L) in reperfused but not in nonreperfused patients. 1 Additionally, hyperglycemia has been shown to be more detrimental early after a stroke when penumbral volume is likely to be at its greatest. Thus, control of hyperglycemia may be more beneficial in patients treated with endovascular therapy, given the greater incidence of reperfusion, larger penumbral volume, and presentation early after AIS onset.
The simplified final score derived from our proposed scale corresponded with poor outcomes, with an AUC value of > 0.79 in both nondiabetic and diabetic patients, and has been validated in a small, retrospective, external cohort of patients. The admission score correlates with the final score, and may be useful for risk-benefit analysis before endovascular therapy and in the selection of mechanical revascularization tools that are associated with a lower risk of sICH and patients who have a lower risk of sICH. Given the retrospective nature of the data from which this score was derived and validated, this scale needs to be prospectively validated before it can be reliably used for prognostication. The zones of prognostication shown in Fig. 6 lower need prospective evaluation, and may ultimately prove useful in the triage of patients for endovascular therapy. This study has all the limitations of a retrospective study. The diabetic status of the study participants was not proactively screened, data regarding therapies that could alter blood glucose values were not included in the analysis, some data points were missing, and a single glucose value after 48 hours of admission was studied. The TIMI Grade 2-3 reperfusion status, NIHSS score, outcomes, and hemorrhages were assessed at individual centers and not by the central coordinating center, and may therefore be subject to variations. The study could have been underpowered to identify other significant predictors that may affect the outcome, especially in diabetic patients. The BRANCH and BAN scales need to be prospectively validated before they can be reliably used for prognostication.
Despite these limitations, this is the largest study to date in which glucose level is analyzed as a prognosticator after endovascular AIS therapy, and that is large enough to identify highly significant predictors. The differences in mortality rate and poor outcome with CG48 in each of the BGA categories (Fig. 1A) offer the possibility of clinically useful triage tiers for endovascular therapy. Moreover, the effects of hyperglycemia on outcomes in AIS in this study meet and exceed those observed in acute MI.
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Our study provides a compelling rationale for the initiation of a glucose-lowering trial in patients with endovascularly treated AIS, with particular emphasis on nondiabetic patients. If prospectively validated, the simplified 3-point admission BAN scale may be easily performed in the emergency room when a stroke patient is being triaged, and may ultimately offer a tool for risk-benefit analysis in endovascular AIS therapy.
Conclusions
Failure of blood glucose values to decrease in the first 48 hours after AIS intervention predicted a poor 90-day outcome in nondiabetic patients, as previously shown after MI intervention in the CARDINAL trial.
12 Although increasing BGA has previously been shown to be associated with an increasing mortality rate with declining functional outcomes in patients with AIS, the cutoff (116 mg/dl) at which it affected the mortality rate in our patients was lower than previously reported. With prospective validation, the BAN and BRANCH scales may aid in prognostication of 90-day clinical outcomes before and after endovascular therapy. Despite the retrospective nature of the data presented brings its attendant limitations, the key observations from our study-glycemic control in nondiabetic patients, tiered correlation of clinical outcomes with a proposed scoring system, and absence of CG48 correlation in diabetic patients-all offer a compelling rationale for further prospective evaluation. 
Fig. 5.
Histograms showing the results of calibration and internal validation by Hosmer-Lemeshow (HL) statistics of the final (upper) and admission (lower) scores. The expected rate of poor outcomes, as calibrated from the scores, and the observed rates of poor outcome in our patient population are plotted against each category of the score in the x axis. Notice that patients with an admission or a final score of ≥ 4 have a dismal 90-day prognosis, and the scores are able to predict the expected outcomes very closely.
